buysellhold july.23

 

UOB KAYHIAN

MAYBANK KIM ENG

Strategy

Yield-ing To Temptation: Yields Over Bonds

 

Highlights

• Attractive yield differentials. With Singapore government bond yields trending lower, the yield differential between fixed income and equities has narrowed in 2025, thus reinforcing the relative appeal of companies offering high, sustainable dividend payouts. Equity yields in the 4-6% range now offer a compelling pickup versus the 10-year Singapore Government Bond yield (1.8579% as at 4 Sep 25), while also providing potential for capital gains. In our view, this widening yield gap should support rotation flows into quality income equities as bond proxies.

 

 

Read More ...



 

Solarvest Holdings (SOLAR MK)

Secures 470MW LSS5+ with Malakoff

 

SOP-TP lifted to MYR2.90; maintain Buy; Top Pick Solarvest has secured the bid under the Energy Commission’s LSS PETRA 5+ exercise, with its consortium (20% Solarvest, 80% Malakoff) receiving a Letter of Notification to develop a 470 MWac solar plant in Perak. The project will be undertaken via a new SPV, which will sign a 21-year SPPA with Tenaga Nasional (TNB). We raise our SOP-TP to MYR2.90 (from MYR2.64), incorporating Solarvest’s 20% stake in the 470MW LSS5+ project. Maintain BUY. Solarvest is our top pick for the sector.

 

 

Read More ...

SAC CAPITAL

UOB KAYHIAN

Livingstone Health Holdings Limited 

 

Company Overview

  • A multidisciplinary healthcare group in Singapore operating primary care and specialist clinics.

  • Services include anaesthesiology, pain management, orthopaedics, podiatry, physiotherapy, aesthetics, and wellness.

  • Structured into Primary Healthcare, Specialist Healthcare, and Others, supported by an integrated care model.


Key Highlights

  • Earnings Turnaround in FY2025: Returned to profitability after losses in FY2024.

  • Revenue: +9% YoY to S$27.6m.

  • EBITDA: Jumped to S$2.9m (10.6% margin) from S$0.5m.

  • Net Profit: S$0.6m (vs loss of S$2.9m in FY2024).

  • Operating Cash Flow: Strong improvement to S$4.3m.

  • Net Cash Position: S$1.0m with additional S$3.0m loan facility for expansion.


Business Developments

  • Acquisition of Phoenix Medical Group: Expanded GP network, enhancing referrals to specialists.

  • New Specialist Clinic: Focused on nerve and muscle disorder diagnostics.

  • Atlas Podiatry: Increased stake to 85% for deeper synergies.

  • Capital Raising: S$2.8m via private placement & rights issue; secured S$3.0m term loan.

  • Technology: Exploring AI tools to improve doctor productivity.


Investment Thesis

  1. Earnings rebound and restored profitability.

  2. Growth from Phoenix Medical Group acquisition.

  3. Expanding specialist services to capture healthcare demand.

  4. Benefiting from Singapore’s ageing population, rising healthcare spend, and Healthier SG policies.

  5. Stronger balance sheet supporting expansion.


Risks

  • Execution and integration challenges with acquisitions.

  • Competitive healthcare market → pressure on retaining talent and patient volumes.

  • Rising costs (staff, rentals, consumables) may squeeze margins.

  • Regulatory risks (changes in Healthier SG policy).


Valuation (FY2025)

  • P/E: 23x

  • EV/EBITDA: 4.6x

  • ROE: 3%

  • Net Profit Margin: 1%

  • Market Cap: S$14.5m, Share Price: S$0.023

  

Oil & Gas – Malaysia

Petronas’ Ongoing Recalibration Against Polycrisis

 

Highlights

Petronas’ resiliency is being tested against a new era of polycrisis. Extending the performance trend in 2024, Petronas’ 1H25 profit/EBITDA declined 19%/15% yoy due to lower realised prices and volumes. Petronas’ financial strength should support its RM32b dividend obligation. However, as described by group CEO Tengku Taufik (TT), long-term cash flow generation is being challenged by an unprecedented polycrisis, including the costs of energy transition alongside an uncertain “deflation” of oil prices, geopolitical and protectionism risks, OPEC+’s unwinding production cuts, and structural shifts in local O&G landscape.

 

 

Read More ...

LIM & TAN  

Marco Polo Marine / MPM ($0.069, up 0.1 cents) announced the selection of Salt Ship Design AS (“Salt”), a renowned Norwegian ship designer, to design the Group’s, next-generation Commissioning Service Operation Vessel – the CSOV Plus. The contract was signed between the Group’s Taiwan-based subsidiary PKR Offshore Co., Ltd, Salt Ship Design and Marco Polo Shipyard Pte Ltd.

MPM’s market cap stands at S$259mln and currently trades at 10.4x FY25F PE and 1.1x PB. The upcoming construction of the CSOV Plus will build on the prospects of its current CSOV, providing increased opportunities in both the offshore wind and oil & gas sectors. We also view the planned listing of its Taiwan subsidiary positively as it affirms MPM’s success in the Taiwan wind market. Maintain BUY on Marco Polo Marine with a target price of S$0.082.

 

 

 

You may also be interested in:


Add comment

 

We have 3284 guests and 2 members online

rss_2 NextInsight - Latest News